Search Results - Spasic, Marko

Characteristics and Management of Superior Semicircular Canal Dehiscence by Yew, Andrew, Zarinkhou, Golmah, Spasic, Marko, Trang, Andy, Gopen, Quinton, Yang, Isaac

Get full text Get full text Get full text

Chromosomal anomalies and prognostic markers for intracranial and spinal ependymomas by Yang, Isaac, Nagasawa, Daniel T., Kim, Won, Spasic, Marko, Trang, Andy, Lu, Daniel C., Martin, Neil A.

Get full text Get full text Get full text

Passive Immunotherapeutic Strategies for the Treatment of Malignant Gliomas by Nagasawa, Daniel T., Fong, Christina, Yew, Andrew, Spasic, Marko, Garcia, Heather M., Kruse, Carol A., Yang, Isaac

Get full text Get full text Get full text

Lifestyle, Physical Activity, Eating and Hygiene Habits: A Comparative Analysis Before and During the COVID-19 Pandemic in Student Population by Sekulic, Marija, Stajic, Dalibor, Jurisic Skevin, Aleksandra, Kocovic, Aleksandar, Zivkovic Zaric, Radica, Djonovic, Nela, Vasiljevic, Dragan, Radmanovic, Branimir, Spasic, Marko, Janicijevic, Katarina, Simic Vukomanovic, Ivana, Niciforovic, Jovan, Parezanovic Ilic, Katarina, Barac, Stevan, Lukovic, Tanja, Joksimovic, Stefan

Get full text Get full text Get full text

Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4(+) T cell Immunity by Binnewies, Mikhail, Mujal, Adriana M., Pollack, Joshua L., Combes, Alexis J., Hardison, Emily A., Barry, Kevin C., Ruhland, Megan K., Kersten, Kelly, Tsui, Jessica, Abushawish, Marwan A., Spasic, Marko, Giurintano, Jonathan P., Chan, Vincent, Daud, Adil I., Ha, Patrick, Ye, Chun J., Roberts, Edward W., Krummel, Matthew F.

Get full text Get full text Get full text

PD-1 blockade induces responses by inhibiting adaptive immune resistance by Tumeh, Paul C., Harview, Christina L., Yearley, Jennifer H., Shintaku, I. Peter, Taylor, Emma J. M., Robert, Lidia, Chmielowski, Bartosz, Spasic, Marko, Henry, Gina, Ciobanu, Voicu, West, Alisha N., Carmona, Manuel, Kivork, Christine, Seja, Elizabeth, Cherry, Grace, Gutierrez, Antonio, Grogan, Tristan R., Mateus, Christine, Tomasic, Gorana, Glaspy, John A., Emerson, Ryan O., Robins, Harlan, Pierce, Robert H., Elashoff, David A., Robert, Caroline, Ribas, Antoni

Get full text Get full text Get full text

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial by Padrón, Lacey J., Maurer, Deena M., O’Hara, Mark H., O’Reilly, Eileen M., Wolff, Robert A., Wainberg, Zev A., Ko, Andrew H., Fisher, George, Rahma, Osama, Lyman, Jaclyn P., Cabanski, Christopher R., Yu, Jia Xin, Pfeiffer, Shannon M., Spasic, Marko, Xu, Jingying, Gherardini, Pier Federico, Karakunnel, Joyson, Mick, Rosemarie, Alanio, Cécile, Byrne, Katelyn T., Hollmann, Travis J., Moore, Jonni S., Jones, Derek D., Tognetti, Marco, Chen, Richard O., Yang, Xiaodong, Salvador, Lisa, Wherry, E. John, Dugan, Ute, O’Donnell-Tormey, Jill, Butterfield, Lisa H., Hubbard-Lucey, Vanessa M., Ibrahim, Ramy, Fairchild, Justin, Bucktrout, Samantha, LaVallee, Theresa M., Vonderheide, Robert H.

Get full text Get full text Get full text